作者: Park, Seoyoung ; Cho, Hanseul ; Jacob, Louis ; Park, Jaeyu ; Lee, Jae E ; Kong, Jaehyun ; Kim, Tae Hyeon ; Pizzol, Damiano ; Lee, Sooji ; Jo, Hyesu ; Lee, Hayeon ; Yon, Dong Keon ; Lee, Jae E. ; Kim, Sunyoung ; Lee, Kyeongmin ; Rhee, Sang Youl ; Oh, Jiyeon

BACKGROUND:

Sarcopenia is a condition that poses a significant risk in the older population, with diabetes identified as a risk factor. Recent evidence suggests that GLP-1 RA, commonly used as antidiabetic treatments, may potentially induce sarcopenia. This study aimed to investigate the association between sarcopenia and various antidiabetic drugs, including GLP-1 RAs.

METHODS:

This study analyzed reports from the World Health Organization international pharmacovigilance database, covering the period from 1967 to 2023 (total reports, n = 131,255,418). We analyzed the reported odds ratio (ROR) and information component (IC) to evaluate the association between sarcopenia and seven classes of antidiabetic drugs: DPP-4 inhibitors, GLP-1 RAs, insulin, metformin, SGLT2 inhibitors, sulfonylureas, and thiazolidinediones.

RESULTS:

Reports of antidiabetic drugs-associated sarcopenia have gradually increased (n = 508; 258 males [50.79 %]). Overall, antidiabetic drugs showed significant associations with sarcopenia (ROR, 1.31 [95 % CI, 1.20-1.44]; IC, 0.38 [IC₀₂₅, 0.24]). Among the individual drug classes, SGLT2 inhibitors showed the highest association (ROR, 2.49 [95 % CI, 1.93-3.22]; IC, 1.30 [IC₀₂₅, 0.87]), followed by metformin (ROR, 1.86 [95 % CI, 1.43-2.41]; IC, 0.88 [IC₀₂₅, 0.44]), DPP-4 inhibitors (ROR, 1.67 [95 % CI, 1.17-2.38]; IC, 0.72 [IC₀₂₅, 0.12]), and insulin (ROR, 1.27 [95 % CI, 1.11-1.45]; IC, 0.34 [IC₀₂₅, 0.11]). Despite the high number of reports for GLP-1 RAs, no significant association with sarcopenia was observed (n = 93; ROR, 1.06 [95 % CI, 0.86-1.29]; IC, 0.08 [IC₀₂₅, -0.27]).

CONCLUSIONS:

Antidiabetic drugs showed significant associations with sarcopenia, with SGLT2 inhibitors exhibiting the strongest association. Notably, despite numerous reports, GLP-1 RAs did not show a significant association.

2024-12-01·Hormones-International Journal of Endocrinology and Metabolism

Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease

Review

作者: Chatzigeorgiou, Antonios ; Kassi, Eva ; Tsioulos, Georgios ; Katsarou, Angeliki

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease, with its incidence increasing in parallel with the global prevalence of obesity and type 2 diabetes mellitus. Despite our steadily increasing knowledge of its pathogenesis, there is as yet no available pharmacotherapy specifically tailored for NAFLD. To define the appropriate management, it is important to clarify the context in which the disease appears. In the case of concurrent metabolic comorbidities, NAFLD patients are treated by targeting these comorbidities, such as diabetes and obesity. Thus, GLP-1 analogs, PPAR, and SGLT2 inhibitors have recently become central to the treatment of NAFLD. In parallel, randomized trials are being conducted to explore new agents targeting known pathways involved in NAFLD progression. However, there is an imperative need to intensify the effort to design new, safe drugs with biopsy-proven efficacy. Of note, the main target of the pharmacotherapy should be directed to the regression of fibrotic NASH, as this histologic stage has been correlated with increased overall as well as liver-related morbidity and mortality. Herein we discuss the drugs currently at the forefront of NAFLD treatment.

2024-12-01·JOURNAL OF GASTROENTEROLOGY

Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan

Article

作者: Io, Fusayo ; Uchida, Saeko ; Fujishima, Yoshiyuki ; Kitajima, Yukiko ; Wakasugi, Daisuke ; Sato, Yuri ; Kawaguchi, Takumi

Abstract:

Background & aim:

SGLT2 inhibitors (SGLT2i) improve hepatic steatosis in patients with type 2 diabetes mellitus (T2DM) and MASLD. We aimed to investigate the impact of SGLT2i on the incidence of liver-related events and extrahepatic cancer compared to DPP4 inhibitors (DPP4i) in patients with T2DM and suspected MASLD using a medical claims database in Japan.

Methods:

We conducted a retrospective study using a Japanese medical claims database. Among patients with T2DM who were prescribed SGLT2i or DPP4i (n = 1,628,656), patients with suspected MASLD were classified into SGLT2i (n = 4204) and DPP4i (n = 4204) groups. Effects of SGLT2i on the following outcomes were compared to DPP4i: (1) changes in HbA1c and ALT levels after 6 months, (2) changes in hepatic fibrosis index, and (3) the incidence of liver-related events/extrahepatic cancer over 12 months.

Results:

After 6 months, DPP4i significantly decreased HbA1c levels compared to SGLT2i. In contrast, SGLT2i significantly decreased ALT levels compared to DPP4i. SGLT2i significantly decreased FIB-4 index compared to DPP4i over 12 months. Although no significant difference was observed in the incidence of overall liver-related events between the two groups, SGLT2i significantly reduced the incidence of esophageal varices (HR 0.12, 95%CI 0.01–0.95, P = 0.044). Moreover, SGLT2i significantly suppressed the incidence of extrahepatic cancer (HR 0.50, 95%CI 0.30–0.84, P = 0.009) compared to DPP4i.

Conclusion:

SGLT2i was more beneficial than DPP4i in improving the hepatic inflammation and fibrosis indices. Moreover, SGLT2i suppressed the incidence of esophageal varices and extrahepatic cancer compared to DPP4i. SGLT2i may suppress life-threatening events in patients with T2DM and suspected MASLD.

项与 SGLT1 inhibitors(China Medical University) 相关的新闻（医药）

2023-08-22

·PRNewswire

Post-bariatric Hypoglycemia in the 7MM: Navigating the Challenges, Opportunities, and Emerging Therapies (2023-2032)

DUBLIN, Aug. 22, 2023 /PRNewswire/ -- The "Post-Bariatric Hypoglycemia Market Insights, Epidemiology and Forecast to 2032" report has been added to ResearchAndMarkets.com's offering. The postbariatric hypoglycemia landscape is marked by both challenges and opportunities. While the US dominates the market, gaps in diagnostic criteria and standardized treatments persist. Emerging therapies like mizagliflozin and AVEXITIDE hold promise in reshaping the treatment paradigm. Future efforts should focus on developing effective treatments tailored to individual needs, considering the variability in patients' responses to current therapies. As the field evolves, innovative solutions are expected to drive significant transformations in the postbariatric hypoglycemia market. Epidemiology and Market Trends In 2022, the United States contributed to about 79% of postbariatric hypoglycemia cases across the 7MM (United States, EU4 countries, and Japan). The US also dominated the market, constituting approximately 89% of the total 7MM market share. Nevertheless, due to the lack of standardized diagnostic criteria, research findings comparison, prevalence rate determination, and uniform treatment approaches remain challenging. The present management landscape involves off-label therapies, which show varying effectiveness. Hence, there's a need for targeted and efficient treatments. Market Dynamics and Players The report delves into the market's future growth potential, encompassing diagnosis rates, disease progression, and treatment guidelines. Furthermore, it comprehensively covers management techniques and emerging therapies, including profiles of late-stage and significant therapies that could reshape the market. Notable players in the postbariatric hypoglycemia treatment arena include Vogenx and Eiger Biopharmaceuticals. The market shares among countries indicate that the US, EU4, the UK, and Japan hold varying sizes, with the US leading significantly. Emerging Therapies The report spotlights two emerging therapies: Mizagliflozin (Vogenx): An orally administered SGLT1 inhibitor, mizagliflozin, targets elevated SGLT1 levels in the gut of postbariatric hypoglycemia patients. This inhibits excessive insulin secretion triggered by elevated blood glucose levels. The drug is in Phase II clinical development. AVEXITIDE (Eiger BioPharmaceuticals): AVEXITIDE is a peptide blocking GLP-1 receptors, curbing dysregulated insulin secretion and reducing fasting and postprandial hypoglycemia. It has earned breakthrough designation for postbariatric hypoglycemia treatment and is progressing towards Phase III trials. Epidemiology and Expert Insights The report offers a comprehensive epidemiological outlook, segregating data by specific bariatric surgery cases, severity-specific PBH cases, and total treated PBH cases. The forecast shows rising cases in the US, EU4, the UK, and Japan. Insights from Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) across prestigious institutions worldwide contribute to a robust understanding of the current and emerging treatment patterns. Qualitative Analysis and Market Access Through techniques like SWOT analysis and Conjoint Analysis, the report assesses various facets, such as disease diagnosis, patient awareness, cost-effectiveness, and therapy accessibility. It also addresses market access and reimbursement issues, exploring factors influencing the entry of innovative treatments into the market. Reimbursement plays a pivotal role in determining the adoption of expensive new drugs. Key Topics Covered 1. Key Insights 2. Report Introduction 3. Postbariatric Hypoglycemia (PBH) Market Overview at a Glance 4. Executive Summary of Postbariatric Hypoglycemia 5. Disease Background and Overview 6. Methodology 7. Epidemiology and Patient Population 8. Patient Journey 9. Emerging Therapies 10. Postbariatric Hypoglycemia (PBH): Seven Major Market Analysis 11. KOL Views 12. SWOT Analysis 13. Unmet Needs 14. Market Access and Reimbursement 15. Appendix A selection of companies mentioned in this report includes: Vogenx Eiger BioPharmaceuticals For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

临床2期临床3期突破性疗法

100 项与 SGLT1 inhibitors(China Medical University) 相关的药物交易

登录后查看更多信息